 "pharma, medicine, drugs")
After the anti-diabetic market, India's cardiology market is now set for a churn as Swiss drugmaker Novartis’ blockbuster drug for heart failure patients Vymada or Entresto is set to go off patent in January.
Trade sources say that this is one of the fastest growing drugs in the Rs 23,000 crore cardiac market in the country.
Entresto or Vymada as it is sold in India is a combination of Sacubitril and Valsartan.
